NEW YORK (GenomeWeb News) – Sirius Genomics will work with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic markers for severe sepsis under a collaborative agreement, the company said today.

Sirius will work with the hospital system's Clinical Research and Development Department in a program aimed at developing a pharmacogenomic diagnostic to assess the responsiveness of severe sepsis patients to recombinant human activated Protein C, which is sold by Eli Lilly under the trade name Xigris.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.